Bayesian Capital Management, LP Gritstone Bio, Inc. Transaction History

Bayesian Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.66 - $3.03 $21,409 - $39,077	-12,897 Reduced 53.07%	11,403 $22,000
Q1 2023 May 15, 2023	BUY	$2.13 - $3.74 $51,759 - $90,882	24,300 New	24,300 $67,000
Q2 2022 Aug 15, 2022	SELL	$1.77 - $4.34 $39,594 - $97,085	-22,370 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.03 - $12.19 $90,151 - $272,690	22,370 New	22,370 $92,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.